Live feed03:00:00·13hPRReleasevia QuantisnowEvaxion reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01ByQuantisnow·Wall Street's wire, on your screen.EVAX· Evaxion A/SHealth Care
